5640

BIOTECHNOLOGY SYSTEMS BRANCH



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/787,436

Source: PCT/09

Date Processed by STIC: 4/21/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.
Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:
http://www.uspto.gov/web/offices/pac/checker

PCT

do not insert <1107 at beginning of each applicant here

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/787,436

DATE: 04/21/2001
TIME: 21:31:43

pgs 1-5

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

Does Not Comply
Corrected Diskette Needed

```
  1 <110> APPLICANT: DELANSORNE, R,mi
W--> 2 <110> APPLICANT: BONNET, Paule
W--> 3 <110> APPLICANT: PARIS, Jacques
  4 <120> TITLE OF INVENTION: Pharmaceutical compositions based on alpha-cyclodextrin
  5       for the oral administration of LH-RH analogues
  6 <130> FILE REFERENCE: H20058-5US
  7 <140> CURRENT APPLICATION NUMBER: US/09/787,436
  8 <141> CURRENT FILING DATE: 2000-03-17
  9 <150> PRIOR APPLICATION NUMBER: PCT/EP99/07389
 10 <151> PRIOR FILING DATE: 1999-09-23
 11 <150> PRIOR APPLICATION NUMBER: EP98402403.4
 12 <151> PRIOR FILING DATE: 1998-09-30
 13 <160> NUMBER OF SEQ ID NOS: 7
 14 <170> SOFTWARE: PatentIn Ver. 2.1
 16 <210> SEQ ID NO: 1
 17 <211> LENGTH: 10
 18 <212> TYPE: PRT
 19 <213> ORGANISM: Artificial Sequence
 20 <220> FEATURE:
 21 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
 22 <221> NAME/KEY: SITE
 23 <222> LOCATION: (1)
 24 <223> OTHER INFORMATION: Xaa is pGlu, D-pGlu, Sar, AcSar, Pro, Ser, D-Ser, Ac-D-Ser,
 25       Thr, D-Thr, Ac-D-Thr or an optionally substituted and/or acylated
 26       aromatic D-amino acid
 27 <221> NAME/KEY: SITE
 28 <222> LOCATION: (2)
 29 <223> OTHER INFORMATION: Xaa His or an optionally substituted aromatic D-amino acid
 30 <221> NAME/KEY: SITE
 31 <222> LOCATION: (3)
 32 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L- or D-amino acid
 33 <221> NAME/KEY: SITE
 34 <222> LOCATION: (4)
 35 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr
 36 <221> NAME/KEY: SITE
 37 <222> LOCATION: (5)
 38 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
 39       or an optionally substituted basic L- or D-amino acid
 40 <221> NAME/KEY: SITE
 41 <222> LOCATION: (6)
 42 <223> OTHER INFORMATION: Xaa is Gly, (S)-spirolactam-Pro, D-Pro, D-Ser, D-Thr,
 43       D-Cys, D-Met, D-Asn, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
 44       D-Ser(OBut), D-Asp(OBut), D-Glu(OBut), D-Thr(OBut),
 45       D-Cys(OBut), D-Ser(OR1) where R1 is a sugar moiety, an
W--> 46 <2237>aza-amino acid, D-His which may be substituted on the
W--> 47 <2237> imidazole ring by a (C1-C6)alkyl, a (C2-C7)acyl or a
W--> 48 <2237> benzyl group, an aliphatic D-amino acid with a (C1-C8)-
```

<2207

Per 1.823 of new Sequence Rules, <2237 responses have a MAXIMUM of 4 lines. Do not exceed. If response is more than 4 lines, add <2207, and new <2237

RAW SEQUENCE LISTING DATE: 04/21/2001
PATENT APPLICATION: US/09/787,436 TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

W--> 49 alkyl or a (C3-C6)cycloalkyl side chain, an optionally
W--> 50 substituted aromatic D-amino acid, D-cyclohexadienyl-Gly,
W--> 51 D-perhydronaphthyl-Ala, D-perhydrodiphenyl-Ala or an
W--> 52 optionally substituted basic L- or D-amino acid
53 <221> NAME/KEY: SITE
54 <222> LOCATION: (7)
55 <223> OTHER INFORMATION: Xaa is a linear, branched or cyclic aliphatic L-amino
56 acid of 3 to 20 carbon atoms which may be N-alpha-
57 substituted by a (C1-C4)alkyl group optionally substituted
58 by one or several fluorine atoms
59 <221> NAME/KEY: SITE
60 <222> LOCATION: (8)
61 <223> OTHER INFORMATION: Xaa is an optionally substituted basic L- or D-amino acid
62 <221> NAME/KEY: SITE
63 <222> LOCATION: (10)
64 <223> OTHER INFORMATION: Xaa is GlyNH2, D-AlaNH2, azaGlyNH2 or a group -NHR2
65 where R2 is a (C1-C4)alkyl which may be substituted by
66 an hydroxy or one or several fluorine atoms, a (C3-
67 C6)cycloalkyl or a heterocyclic radical selected from
W--> 68 morpholinyl, pyrrolidinyl and piperidyl
69 <400> SEQUENCE: 1
W--> 70 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
71 1 5 10
73 <210> SEQ ID NO: 2
74 <211> LENGTH: 10
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
79 <221> NAME/KEY: SITE
80 <222> LOCATION: (1)
81 <223> OTHER INFORMATION: Xaa is pGlu, Sar or AcSar
82 <221> NAME/KEY: SITE
83 <222> LOCATION: (3)
84 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
85 <221> NAME/KEY: SITE
86 <222> LOCATION: (4)
87 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr
88 <221> NAME/KEY: SITE
89 <222> LOCATION: (5)
90 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
91 <221> NAME/KEY: SITE
92 <222> LOCATION: (6)
93 <223> OTHER INFORMATION: Xaa is Gly, (S)-spirolactam-Pro, D-Pro, D-Ser, D-Thr,
94 D-Cys, D-Met, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
95 D-Ser(OBut), D-Asp(OBut), D-Glu(OBut), D-Thr(OBut),
96 D-Cys(OBut), D-Ser(OR1) where R1 is a sugar moiety, an
W--> 97 aza-amino acid, D-His which may be substituted on the
W--> 98 imidazole ring by a (C1-C6)alkyl or a benzyl group, an

FYI: Xaa can only represent a single amino acid, nothing else

RAW SEQUENCE LISTING DATE: 04/21/2001
PATENT APPLICATION: US/09/787,436 TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

W--> 99 <2237>aliphatic D-amino acid with a (C1-C8)alkyl or a (C3-
W--> 100 <2237> C6)cycloalkyl side chain, an optionally substituted
W--> 101 <2237> aromatic D-amino acid, D-cyclohexadienyl-Gly, D-
W--> 102 <2237> perhydronaphthyl-Ala, D-perhydrodiphenyl-Ala or an
W--> 103 <2237>optionally substituted basic D-amino acid
104 <221> NAME/KEY: SITE
105 <222> LOCATION: (7)
106 <223> OTHER INFORMATION: Xaa is a linear, branched or cyclic aliphatic L-amino
107 acid of 3 to 20 carbon atoms which may be N-alpha-
108 substituted by a (C1-C4)alkyl group optionally substituted
109 by one or several fluorine atoms
110 <221> NAME/KEY: SITE
111 <222> LOCATION: (8)
112 <223> OTHER INFORMATION: Xaa is an optionally substituted basic L-amino acid
113 <221> NAME/KEY: SITE
114 <222> LOCATION: (10)
115 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or a group -NHR2 where R2 is
116 a (C1-C4)alkyl which may be substituted by an hydroxy
117 or one or several fluorine atoms, a (C3-C6)cycloalkyl
118 or a heterocyclic radical selected from morpholinyl,
W--> 119 <2237>pyrrolidinyl and piperidyl
120 <400> SEQUENCE: 2
W--> 121 Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
122 1 5 10
124 <210> SEQ ID NO: 3
125 <211> LENGTH: 10
126 <212> TYPE: PRT
127 <213> ORGANISM: Artificial Sequence
128 <220> FEATURE:
129 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
130 <221> NAME/KEY: SITE
131 <222> LOCATION: (1)
132 <223> OTHER INFORMATION: Xaa is pGlu
133 <221> NAME/KEY: SITE
134 <222> LOCATION: (3)
135 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
136 <221> NAME/KEY: SITE
137 <222> LOCATION: (5)
138 <223> OTHER INFORMATION: Xaa is as defined for SED ID NO:2
139 <221> NAME/KEY: SITE
140 <222> LOCATION: (6)
141 <223> OTHER INFORMATION: Xaa is as defined for SED ID NO:2
142 <221> NAME/KEY: SITE
143 <222> LOCATION: (7)
144 <223> OTHER INFORMATION: Xaa is Leu, Tle, Nle, Hol, Npg, Cha or Ada, which may
145 be N-alpha-substituted by a methyl or ethyl group
146 optionally substituted by one or several fluorine atoms
147 <221> NAME/KEY: SITE
148 <222> LOCATION: (10)

FYI! Xaa can only represent a single amino acid

RAW SEQUENCE LISTING DATE: 04/21/2001
PATENT APPLICATION: US/09/787,436 TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

149 <223> OTHER INFORMATION: Xaa is as defined for SEQ ID NO:2
150 <400> SEQUENCE: 3
W--> 151 Xaa His Xaa Ser Xaa Xaa Xaa Arg Pro Xaa
152 1 5 10
154 <210> SEQ ID NO: 4
155 <211> LENGTH: 10
156 <212> TYPE: PRT
157 <213> ORGANISM: Artificial Sequence
158 <220> FEATURE:
159 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
160 <221> NAME/KEY: SITE
161 <222> LOCATION: (1)
162 <223> OTHER INFORMATION: Xaa is pGlu
163 <221> NAME/KEY: SITE
164 <222> LOCATION: (3)
165 <223> OTHER INFORMATION: Xaa is Phe, Tyr, Trp, 2MeTrp, HPhe, HTyr, Nal, 1Nal,
166 Bal, Pal, 4Pal or pClPhe
167 <221> NAME/KEY: SITE
168 <222> LOCATION: (5)
169 <223> OTHER INFORMATION: Xaa is Phe, Tyr, Trp, 2MeTrp, HPhe, HTyr, Nal, 1Nal,
170 Bal, Pal, 4Pal or pClPhe
171 <221> NAME/KEY: SITE
172 <222> LOCATION: (6)
173 <223> OTHER INFORMATION: Xaa is (S)-spirolactam-Pro, Gly, D-Pro, D-Ser(OBut),
174 D-Asp(OBut), D-Glu(OBut), D-Thr(OBut), D-Cys(OBut),
175 D-His, D-His(Bzl), D-Ala, D-Leu, D-Tle, D-Nle, D-Hol,
176 D-Npg, D-Cha, D-Phe, D-HPhe, D-Tyr, D-HTyr, D-Trp, → L2207
W--> 177 L2237 D-2MeTrp, D-Nal, D-1Nal, D-Bal, D-Pal, D-4Pal, D-pClPhe
W--> 178 L2237 D-cyclohexadienyl-Gly, D-perhydronaphtyl-Ala,
W--> 179 L2237 D-perhydrodiphenyl-Ala or D-APhe optionally substituted
W--> 180 L2237 by an aminotriazolyl group
181 <221> NAME/KEY: SITE
182 <222> LOCATION: (7)
183 <223> OTHER INFORMATION: Xaa is Leu, Npg or Cha, which may be N-alpha-substituted
184 by a methyl group
185 <221> NAME/KEY: SITE
186 <222> LOCATION: (10)
187 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or -NC2H5
188 <400> SEQUENCE: 4
W--> 189 Xaa His Xaa Ser Xaa Xaa Xaa Arg Pro Xaa
190 1 5 10
192 <210> SEQ ID NO: 5
193 <211> LENGTH: 10
194 <212> TYPE: PRT
195 <213> ORGANISM: Artificial Sequence
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
198 <221> NAME/KEY: SITE
199 <222> LOCATION: (1)

RAW SEQUENCE LISTING DATE: 04/21/2001
PATENT APPLICATION: US/09/787,436 TIME: 21:31:43

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

```
   200 <223> OTHER INFORMATION: Xaa is pGlu
   201 <221> NAME/KEY: SITE
   202 <222> LOCATION: (6)
   203 <223> OTHER INFORMATION: Xaa is (S)-spirolactam-Pro, D-Leu, D-Ala, D-Nal,
   204       D-Phe, D-Ser(OBut) or D-Trp
   205 <221> NAME/KEY: SITE
   206 <222> LOCATION: (7)
   207 <223> OTHER INFORMATION: Xaa is Leu, MeLeu, Npg or MeNpg
   208 <221> NAME/KEY: SITE
   209 <222> LOCATION: (10)
   210 <223> OTHER INFORMATION: Xaa is GlyNH2, azaGlyNH2 or -NC2H5
   211 <400> SEQUENCE: 5
W--> 212           Xaa His Trp Ser Tyr Xaa Xaa Arg Pro Xaa
   213             1               5                  10
   215 <210> SEQ ID NO: 6
   216 <211> LENGTH: 10
   217 <212> TYPE: PRT
   218 <213> ORGANISM: Artificial Sequence
   219 <220> FEATURE:
   220 <223> OTHER INFORMATION: Description of Artificial Sequence:LH-RH analogue
   221 <221> NAME/KEY: SITE
   222 <222> LOCATION: (1)
   223 <223> OTHER INFORMATION: Xaa is pGlu, D-pGlu, Sar, AcSar, Pro thereof, Ser, D-Ser,
   224       Ac-D-Ser, Thr, D-Thr, Ac-D-Thr or an optionally substituted
   225       and/or acylated aromatic D-amino acid
   226 <221> NAME/KEY: SITE
   227 <222> LOCATION: (2)
   228 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic D-amino acid
   229 <221> NAME/KEY: SITE
   230 <222> LOCATION: (3)
   231 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L- or D-amino acid
   232 <221> NAME/KEY: SITE
   233 <222> LOCATION: (4)
   234 <223> OTHER INFORMATION: Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr
   235 <221> NAME/KEY: SITE
   236 <222> LOCATION: (5)
   237 <223> OTHER INFORMATION: Xaa is an optionally substituted aromatic L-amino acid
   238       or an optionally substituted basic L- or D-amino acid
   239 <221> NAME/KEY: SITE
   240 <222> LOCATION: (6)
   241 <223> OTHER INFORMATION: Xaa is Gly, (S)-spirolactam-Pro, D-Pro, D-Ser, D-Thr,
   242       D-Cys, D-Met, D-Asn, D-Pen, D-(S-Me)Pen, D-(S-Et)Pen,
   243       D-Ser(OBut), D-Asp(OBut), D-Glu(O-But), D-Thr(O-But),
   244       D-Cys(O-But), D-Ser(O-R1) where R1 is a sugar moiety,
W--> 245 <2237> an aliphatic D-amino acid with a (C1-C8)alkyl or a
W--> 246 <2237> (C3-C6)cycloalkyl side chain, an optionally substituted
W--> 247 <2237> aromatic D-amino acid, D-cyclohexadienyl-Gly, D-
W--> 248 <2237> perhydronaphthyl-Ala, D-perhydrodiphenyl-Ala or an
W--> 249 <2237> optionally substituted basic L- or D-amino acid
```

<2207>

<2207>

PSL

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY DATE: 04/21/2001
PATENT APPLICATION: US/09/787,436 TIME: 21:31:44

Input Set : N:\Crf3\04042001\I787436.raw
Output Set: N:\CRF3\04202001\I787436.raw

L:2 M:280 W: Numeric Identifier already exists, <110> found multiple times
L:3 M:280 W: Numeric Identifier already exists, <110> found multiple times
L:46 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:47 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:48 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:49 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:50 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:51 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:52 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:68 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:70 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:97 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:98 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:99 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:100 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:101 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:102 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:103 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:119 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:121 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:151 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:177 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:178 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:179 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:180 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:212 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:245 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:246 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:247 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:248 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:249 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:263 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:298 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7